What is the recommended dose of Voriconazole (Voriconazole) for an adult patient with a fungal infection and potential impaired renal (Renal Impairment) or hepatic (Hepatic Impairment) function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 22, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Voriconazole Dosing Recommendations

For adult patients with fungal infections, initiate voriconazole with a loading dose of 6 mg/kg (or 400 mg) every 12 hours for two doses on day 1, followed by a maintenance dose of 3-4 mg/kg (or 200-300 mg) every 12 hours, with critical modifications required for renal and hepatic impairment. 1, 2, 3

Standard Dosing Regimen

Intravenous Administration

  • Loading dose: 6 mg/kg IV every 12 hours for the first 24 hours (420 mg for a 70 kg patient) 1, 2, 3
  • Maintenance dose: 3-4 mg/kg IV every 12 hours (210-280 mg for a 70 kg patient) 1, 2, 3
  • Continue IV therapy for minimum 7 days until clinical improvement allows transition to oral therapy 2

Oral Administration

  • Loading dose: 400 mg (6 mg/kg) orally every 12 hours for two doses 1, 3
  • Maintenance dose: 200-300 mg (3-4 mg/kg) orally every 12 hours 1, 3
  • Oral bioavailability exceeds 90%, allowing seamless IV-to-oral transition 1
  • Critical: Take at least 1 hour before or after meals, as food significantly reduces bioavailability 1

Dose Adjustments for Inadequate Response

  • If response is inadequate, increase oral maintenance from 200 mg to 300 mg every 12 hours 3
  • If unable to tolerate 300 mg orally, reduce by 50 mg increments to minimum 200 mg every 12 hours 3
  • For IV therapy, if unable to tolerate 4 mg/kg, reduce to 3 mg/kg every 12 hours 3

Critical Dosing Modifications for Renal Impairment

Avoid intravenous voriconazole in patients with creatinine clearance <50 mL/min due to accumulation of the nephrotoxic vehicle sulfobutylether-β-cyclodextrin (SBECD). 1, 2, 4, 3

Route Selection Based on Renal Function

  • CrCl <50 mL/min: Use oral voriconazole at standard doses without adjustment 1, 4, 3
  • CrCl ≥50 mL/min: Either IV or oral formulation acceptable 4
  • Hemodialysis patients: Oral voriconazole preferred; no dose adjustment needed as 4-hour hemodialysis removes insufficient drug 3

Important Caveat

While guidelines recommend avoiding IV voriconazole in renal impairment, retrospective data from 166 ICU patients showed that IV administration in patients with CrCl <50 mL/min was not independently associated with worsening renal dysfunction 5. However, the guideline recommendation to use oral formulation remains the standard of care 1, 2, 4.

Critical Dosing Modifications for Hepatic Impairment

Voriconazole is the only triazole requiring dose reduction in hepatic impairment. 1, 4

Hepatic Dosing Algorithm

  • Mild to moderate hepatic impairment (Child-Pugh Class A or B):

    • Use standard loading dose (6 mg/kg or 400 mg every 12 hours × 2 doses) 1, 4, 3
    • Reduce maintenance dose by 50% (1.5-2 mg/kg IV or 100-150 mg orally every 12 hours) 1, 2, 4, 3

  • Severe hepatic impairment (Child-Pugh Class C):

    • No pharmacokinetic data available 3
    • Use only if benefit outweighs risk with careful monitoring for toxicity 3

Rationale

Hepatic impairment increases voriconazole AUC by 2.3-fold (mild) to 3.2-fold (moderate) compared to normal function 3. The 50% maintenance dose reduction in moderate impairment achieves similar AUC to standard dosing in normal hepatic function 3.

Indication-Specific Dosing

Invasive Aspergillosis

  • Loading: 6 mg/kg IV every 12 hours × 2 doses 2, 3
  • Maintenance: 4 mg/kg IV every 12 hours for minimum 7 days, then 200 mg orally every 12 hours 2, 3
  • Duration: Minimum 6-12 weeks; continue throughout immunosuppression until lesion resolution 2
  • Median treatment duration in trials: 10 days IV followed by 76 days oral 1, 3

Candidemia and Deep Tissue Candida Infections

  • Candidemia (non-neutropenic): 3 mg/kg IV every 12 hours as primary therapy 3
  • Deep tissue infections: 4 mg/kg IV every 12 hours as salvage therapy 3
  • Duration: 2 weeks after documented blood culture clearance and symptom resolution 1

Esophageal Candidiasis

  • Oral only: 200 mg every 12 hours 3
  • IV formulation not evaluated for this indication 3

Scedosporiosis and Fusariosis

  • Loading: 6 mg/kg IV every 12 hours × 2 doses 3
  • Maintenance: 4 mg/kg IV every 12 hours, then 200 mg orally every 12 hours 3

Therapeutic Drug Monitoring

Strongly recommended due to high interpatient variability from CYP2C19 polymorphisms. 1, 2, 4

  • Target therapeutic range: 1-4 mcg/mL 2
  • Particularly important in critically ill patients and with oral therapy 1
  • Common CYP2C19 polymorphisms cause wide variability in serum levels 1, 4

Critical Drug Interactions

Voriconazole is both substrate and inhibitor of CYP2C19, CYP2C9, and CYP3A4. 4, 6

Contraindicated Combinations

  • Rifampin: Decreases voriconazole Cmax and AUC by 93% and 96%; even doubling voriconazole dose inadequate 3
  • High-dose ritonavir (400 mg): Decreases voriconazole Cmax and AUC by 66% and 82% 3
  • Low-dose ritonavir (100 mg): Decreases voriconazole Cmax and AUC by 24% and 39% 3

Review all concurrent medications before initiating therapy 2, 4.

Common Pitfalls to Avoid

  1. Do not use IV voriconazole as first-line in CrCl <50 mL/min when oral formulation is feasible 4
  2. Do not adjust oral voriconazole doses based on renal function - this leads to subtherapeutic levels 4
  3. Do not use voriconazole for urinary candidiasis - it does not accumulate in active form in urine 1
  4. Do not forget to halve maintenance dose in hepatic impairment - this is unique to voriconazole among triazoles 1, 4
  5. Monitor serum creatinine closely if IV formulation used in renal impairment - consider switching to oral if creatinine rises 3

Monitoring Requirements

  • Hepatotoxicity: Monitor liver function tests; voriconazole associated with elevated transaminases in up to 20% of patients 1, 6
  • Visual disturbances: Occur in approximately 30% of patients; dose-related but typically reversible 1, 7
  • Other adverse effects: Photosensitivity, periostitis, CNS effects more common with higher concentrations 1

Special Populations

Patients <40 kg Body Weight

  • Reduce oral maintenance dose by 50% (100 mg every 12 hours, or 150 mg if inadequate response) 3

Elderly Patients (≥65 years)

  • No dose adjustment necessary despite 80-90% higher plasma concentrations 3
  • Safety profile similar to younger patients 3

References

1
Guideline

Voriconazole Dosing and Administration

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

2
Guideline

Voriconazole Dosing for Aspergillus Infection

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

4
Guideline

Voriconazole Dosing in Renal Impairment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

5
Research

Administration of voriconazole in patients with renal dysfunction.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012

6
Research

Voriconazole.

Clinical therapeutics, 2003

Related Questions

What is the recommended Voriconazole (Voriconazole) dose for a patient with impaired renal function (creatinine clearance of 25)?
What is the treatment regimen for severe fungal infections using Voriconazole?
What is the recommended dose of voriconazole (antifungal medication) in Intensive Care Unit (ICU) patients with impaired renal (kidney) function or hepatic (liver) impairment?
What is the recommended dosage of voriconazole for a patient with pulmonary mycetoma of fungal origin?
What is the recommended dosage and indications for Voriconazole (Voriconazole) in treating fungal infections, specifically invasive aspergillosis and candidiasis?
What are the potential complications and necessary monitoring for a Large for Gestational Age (LGA) newborn from a mother with gestational diabetes, who had a prolonged rupture of membranes (PROM) for 25 hours, and presents with sacral dimpling?
What is the best course of action for an elderly male patient presenting with impaired renal function, as evidenced by elevated urea and creatinine levels, and a low BUN (Blood Urea Nitrogen) to creatinine ratio?
What is the preferred type of colostomy, sigmoid or transverse, for a patient with stage IV (fourth stage) rectal cancer?
What are the treatment options for a patient with recurrent conjunctival melanoma?
What is the management approach for a patient with rheumatoid arthritis (RA) and a history of autoimmune disease, taking Actemra (tocilizumab) who develops oral ulcers?
What considerations should be taken when prescribing Droperidol to a patient with hypertension for pain management?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question